From what 1 stock analysts predict, the share price for ICU Medical Inc (ICUI) might increase by 4.57% in the next year. This is based on a 12-month average estimation for ICUI. Price targets go from $110.00 to $110.00. The majority of stock analysts believe ICUI is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assigned ICUI 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect ICU Medical Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ICUI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
kristen stewart C.L. King | Buy | $110.0 | initiatedcoverage | Dec 14, 2023 |
matthew mishan KeyBanc | Buy | $216.0 | maintained | May 9, 2023 |
jayson bedford Raymond James | Hold | None | downgraded | Nov 8, 2022 |
john ransom Raymond James | Buy | None | maintained | Aug 1, 2018 |
lawrence keusch Raymond James | Buy | $265.0 | reiterated | Mar 8, 2018 |
jennie tsai Gabelli | Buy | None | maintained | Nov 13, 2017 |
brooks west Piper Sandler | Hold | $123.0 | reiterated | Jan 5, 2017 |
thomas gunderson Piper Sandler | Buy | $129.0 | maintained | Jan 14, 2016 |
lawrence solow CJS Securities | Buy | $80.0 | upgraded | Sep 23, 2014 |
james terwilliger Northland Securities | Hold | $69.0 | downgraded | May 9, 2013 |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 brand; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; professional services; critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
When did it IPO
1992
Staff Count
14,500
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Vivek Jain
Market Cap
$2.57B
In 2023, ICUI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ICUI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
FTDR-USD
$32.53
$25.99
MYRG-USD
$154.12
DORM-USD
$82.82
$16.01
PINC-USD
$21.34